Aurobindo Pharma Ltd. Fundamental & Technical Research, Share Price Today

NSE : AUROPHARMA
NIFTY : NIFTY Midcap 100
NIFTY SECTOR : Nifty Pharma

About Company

Aurobindo Pharma Limited continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.

Market Cap. ₹68,323 Cr.

52 Week - High/Low ₹1,592/1,031

P/E Ratio 35.82

P/B Ratio 3.46

Enterprise Value ₹71,628 Cr.

ROE % 10.06

RSI Value 56.00

EMA 50 1159.52

EMA 200 1222.36

Net Profit 1,954 Cr.

Net Profit 3year growth -37.22 Cr.

Net Profit 3 year (back) 3,113 Cr.

Debt to Equity 0.14 %

EPS Growth TTM -4.78 %

Current Ratio 1.35 %

100 Day SMA 1,198 Rs.

200 Day SMA 1,313 Rs.

21 Day SMA 1,132 Rs.

50 Day SMA 1,145 Rs.

Book Value 340 Rs.

EV/EBITDA Ratio 23

QoQ EPS Growth -12 %

QoQ Operating Profit Growth -1 %

QoQ Sales Growth 3 %

Sales Latest Quarter 2,884 Cr.

YoY Sales Growth 8 %

Market Cap. ₹68,323 Cr.

52 Week - High/Low ₹1,592/1,031

P/E Ratio 19.68

P/B Ratio 2.29

Enterprise Value ₹63,853 Cr.

ROE % 11.18

RSI Value 56.00

EMA 50 1159.52

EMA 200 1222.36

Net Profit 3,173 Cr.

Net Profit 3year growth 3.21 Cr.

Net Profit 3 year (back) 5,335 Cr.

Debt to Equity 0.21 %

EPS Growth TTM 26.48 %

Current Ratio 1.95 %

100 Day SMA 1,198 Rs.

200 Day SMA 1,313 Rs.

21 Day SMA 1,132 Rs.

50 Day SMA 1,145 Rs.

Book Value 514 Rs.

EV/EBITDA Ratio 9

QoQ EPS Growth 3 %

QoQ Operating Profit Growth 1 %

QoQ Sales Growth 2 %

Sales Latest Quarter 7,893 Cr.

YoY Sales Growth 9 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages